Allergy

Lieberman discusses atypical anaphylaxis signs in infants and toddlers and why epinephrine remains underused.

Rima Rachid, MD, discusses the purified MTT formulation, phase 2 trial design, and the gut bacteria driving protection against peanut allergy.

The bispecific TSLP/IL-13 inhibitor BEL512 met its primary endpoint and all secondary endpoints in adults with chronic rhinosinusitis with nasal polyps.

Stay updated with the latest healthcare breakthroughs, including phase 3 sibeprenlimab data in IgAN and the FDA approval of oveporexton for narcolepsy.

Aquestive Therapeutics reported human factors and pharmacokinetic data supporting a planned third-quarter 2026 resubmission of the Anaphylm NDA for Type 1 allergic reactions.

Merve Karaca Şahin, MD, discusses fear- and picky-eating-driven ARFID behaviors in children with food allergy.

A prospective cohort study found 94% of patients tolerated direct initiation at maintenance OIT dosing after brief omalizumab pretreatment.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

The FDA has granted Fast Track designation to PVX108, Aravax's investigational peptide immunotherapy for peanut allergy, ahead of phase 2 data expected later in 2026.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

NYC allergists discuss tapinarof's 80-day treatment-free interval, ruxolitinib's box warning hurdles, and more.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

A FARE Patient Registry analysis finds herb and spice allergies disproportionately affect Black, Hispanic, and lower-income patients, Carolyn Baloh, MD, says.

Thanai Pongdee, MD, discusses how PIONEER data reveal quality of life gains that go beyond symptom and biomarker control in indolent systemic mastocytosis.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat improved quality of life for HAE patients already stable on long-term prophylaxis.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat quickly resolves breakthrough HAE attacks in patients on long-term prophylaxis

David B.K. Golden, MD, of Johns Hopkins, discusses anaphylaxis counseling, the Anaphylm CRL, and why a new epinephrine guideline is still years away.

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

Interim KONFIDENT-S data show breakthrough HAE attacks began to be relieved at a median of 1.2 hours.

FDA expands RYALTRIS® approval to children aged 6 to 11 with seasonal allergic rhinitis, based on phase 3 trial data.